Asymmetric and unilateral hearing loss in children

Vila, Peter M.; Lieu, Judith E. C.

doi:10.1007/s00441-015-2208-6

Cited by 64 publications

(57 citation statements)

References 71 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The causes of SSD and asymmetrical hearing loss (AHL) are various, including idiopathic sudden sensorineural hearing loss (SSNHL), acoustic neuroma, anomalies of the inner ear, cochlear nerve deficiency (CND), mumps, congenital cytomegalovirus (CMV) infection, meningitis and auditory neuropathy spectrum disorder (ANSD) [4]. Some cases of SSD and AHL with particular etiologies are progressive in nature.…”

Section: Introductionmentioning

confidence: 99%

Etiology of single-sided deafness and asymmetrical hearing loss

Usami

Kitoh

Moteki

et al. 2017

Acta Oto-Laryngologica

View full text Add to dashboard Cite

In our cohort of congenital/early-onset SSD (n = 210), the most prevalent cause in children was cochlear nerve deficiency (43.7%; 87 of 199 patients undergoing CT and/or MRI), followed by CMV infection, mumps infection, anomalies of the inner ear, ANSD, and other rare etiologies. In contrast, half of the adult SSD patients presented with idiopathic sensorineural hearing loss, followed by various types of otitis media, cerebellopontine angle tumor and other rare etiologies.

show abstract

Section: Introductionmentioning

confidence: 99%

Etiology of single-sided deafness and asymmetrical hearing loss

Usami

Kitoh

Moteki

et al. 2017

Acta Oto-Laryngologica

View full text Add to dashboard Cite

show abstract

“…Importantly, AHL may have a significant impact on childhood cancer survivors. Children with AHL may have difficulties in communication, achieving developmental milestones, understanding speech, localizing sounds, and learning in classroom settings . Self‐esteem can also be impacted .…”

Section: Discussionmentioning

confidence: 99%

Asymmetric sensorineural hearing loss is a risk factor for late‐onset hearing loss in pediatric cancer survivors following cisplatin treatment

Robertson¹,

Hayashi

Camet

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Ototoxicity is a significant complication of cisplatin treatment. Hearing loss can be symmetric or asymmetric, and may decline after therapy. This study examined the risks of asymmetric and late-onset hearing loss (LOHL) in cisplatin-treated pediatric patients with cancer. Methods:A retrospective review of 993 patients' medical and audiological charts from August 1990 to March 2015 was conducted using stringent criteria to characterize patients with asymmetric hearing loss (AHL) or LOHL. Audiologic data were reviewed for 248 patients that received cisplatin to assess cisplatin-induced sensorineural hearing loss and its associated risk factors.Results: Of the patients evaluable for AHL, 26% exhibited this finding. Of those evaluable for LOHL, 42% of the patients' hearing worsened more than 6 months after therapy completion. Radiation and type of cancer diagnosis were major risk factors for both AHL and LOHL. Furthermore, LOHL was linked to age of diagnosis, noncranial radiation, and longer audiologic follow-up. AHL was strongly associated with LOHL-60% of patients with AHL also had LOHL. Logistic regression analysis revealed that patients with AHL (OR 6.3, 95% CI: 2.2-17.8, P = 0.0005) or those receiving radiation (OR 3.2, 95% CI: 1.2-8.6, P = 0.02) were at greatest risk for LOHL. Conclusion:Children receiving cisplatin therapy are at risk for developing AHL and LOHL. Those that have received radiation and/or with AHL are at increased risk for further hearing decline.Long-term monitoring of these patients is important for early intervention as hearing diminishes. K E Y W O R D Sasymmetric, cisplatin, hearing loss, late-onset, pediatric

show abstract

“…However, genetic examination might not be valuable in determining the cause of ASNHL. To date, there are no genetic mutations reported to be specifically associated with unilateral hearing loss [39].…”

Section: Discussionmentioning

confidence: 99%

Silent Vestibulopathy in Asymmetric Hearing Loss Can Be a Sign of a Cerebellopontine Angle Tumor

Sunwoo

Jeon

Park

et al. 2018

JOHBM

View full text Add to dashboard Cite

Abstract:The presence of an ipsilateral cerebellopontine angle (CPA) tumor should be ruled out in patients with asymmetric sensorineural hearing loss (ASNHL). Although many patients with CPA tumors have ipsilateral vestibular hypofunction, some of them do not experience dizziness even with ipsilateral vestibular hypofunction. We analyzed the incidence of CPA tumors among patients with ASNHL without subjective dizziness based on the presence of vestibulopathy. We hypothesized that a patient with silent unilateral vestibular hypofunction (UVH) is more likely to be diagnosed with a CPA tumor. Among 157 subjects who underwent MRI for ASNHL, those who did not have "subjective dizziness" were selected. All subjects underwent hearing and vestibular function tests. UVH was diagnosed if canal paresis ≥ 25%, positive head-shake nystagmus, or gain of head-impulse test < 0.8 were detected. The diameters of the CPA tumors were measured along the petrosal ridge on the axial plane of MRI. Among the enrolled subjects, 44 (28.02%) were diagnosed with a CPA tumor. The 37 patients (84.1%) with a CPA tumor had silent UVH, while only 33 of the 113 patients (29.2%) without a CPA tumor had silent UVH (chi-square test, odds ratio = 12.8, p < 0.001). Silent UVH in patients with ASNHL may be a sign of a CPA tumor.

show abstract

Asymmetric and unilateral hearing loss in children

Cited by 64 publications

References 71 publications

Etiology of single-sided deafness and asymmetrical hearing loss

Etiology of single-sided deafness and asymmetrical hearing loss

Asymmetric sensorineural hearing loss is a risk factor for late‐onset hearing loss in pediatric cancer survivors following cisplatin treatment

Silent Vestibulopathy in Asymmetric Hearing Loss Can Be a Sign of a Cerebellopontine Angle Tumor

Contact Info

Product

Resources

About